CO2018005139A2 - Proceso para preparar una formulación en polvo seco que comprende un anticolinérgico, un corticosteroide y un beta-adrenérgico - Google Patents

Proceso para preparar una formulación en polvo seco que comprende un anticolinérgico, un corticosteroide y un beta-adrenérgico

Info

Publication number
CO2018005139A2
CO2018005139A2 CONC2018/0005139A CO2018005139A CO2018005139A2 CO 2018005139 A2 CO2018005139 A2 CO 2018005139A2 CO 2018005139 A CO2018005139 A CO 2018005139A CO 2018005139 A2 CO2018005139 A2 CO 2018005139A2
Authority
CO
Colombia
Prior art keywords
anticholinergic
corticosteroid
dry powder
powder formulation
adrenergic
Prior art date
Application number
CONC2018/0005139A
Other languages
English (en)
Spanish (es)
Inventor
Claudio Cafiero
Leonardo Ortenzi
Original Assignee
Chiesi Farm Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54548063&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO2018005139(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Chiesi Farm Spa filed Critical Chiesi Farm Spa
Publication of CO2018005139A2 publication Critical patent/CO2018005139A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pain & Pain Management (AREA)
  • Otolaryngology (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CONC2018/0005139A 2015-11-16 2018-05-16 Proceso para preparar una formulación en polvo seco que comprende un anticolinérgico, un corticosteroide y un beta-adrenérgico CO2018005139A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP15194661 2015-11-16
PCT/EP2016/077566 WO2017085007A1 (en) 2015-11-16 2016-11-14 A process for preparing a dry powder formulation comprising an anticholinergic, a corticosteroid and a beta-adrenergic

Publications (1)

Publication Number Publication Date
CO2018005139A2 true CO2018005139A2 (es) 2018-08-10

Family

ID=54548063

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2018/0005139A CO2018005139A2 (es) 2015-11-16 2018-05-16 Proceso para preparar una formulación en polvo seco que comprende un anticolinérgico, un corticosteroide y un beta-adrenérgico

Country Status (31)

Country Link
US (3) US10086003B2 (cg-RX-API-DMAC10.html)
EP (2) EP3377109B1 (cg-RX-API-DMAC10.html)
JP (1) JP6942126B2 (cg-RX-API-DMAC10.html)
KR (1) KR20180082442A (cg-RX-API-DMAC10.html)
CN (1) CN108348614B (cg-RX-API-DMAC10.html)
AR (1) AR106687A1 (cg-RX-API-DMAC10.html)
AU (1) AU2016357988B2 (cg-RX-API-DMAC10.html)
CA (1) CA3005291C (cg-RX-API-DMAC10.html)
CL (1) CL2018001297A1 (cg-RX-API-DMAC10.html)
CO (1) CO2018005139A2 (cg-RX-API-DMAC10.html)
DK (2) DK3377109T3 (cg-RX-API-DMAC10.html)
EA (1) EA037346B1 (cg-RX-API-DMAC10.html)
ES (2) ES2789365T3 (cg-RX-API-DMAC10.html)
GE (2) GEP20207178B (cg-RX-API-DMAC10.html)
HR (2) HRP20211599T1 (cg-RX-API-DMAC10.html)
HU (2) HUE050343T2 (cg-RX-API-DMAC10.html)
IL (1) IL259327B (cg-RX-API-DMAC10.html)
MA (1) MA52437A (cg-RX-API-DMAC10.html)
MX (1) MX377113B (cg-RX-API-DMAC10.html)
MY (1) MY198321A (cg-RX-API-DMAC10.html)
PE (1) PE20181377A1 (cg-RX-API-DMAC10.html)
PH (1) PH12018501023A1 (cg-RX-API-DMAC10.html)
PL (2) PL3689379T3 (cg-RX-API-DMAC10.html)
PT (2) PT3689379T (cg-RX-API-DMAC10.html)
SA (1) SA518391574B1 (cg-RX-API-DMAC10.html)
SG (2) SG10201912090UA (cg-RX-API-DMAC10.html)
SI (2) SI3689379T1 (cg-RX-API-DMAC10.html)
TW (1) TWI729025B (cg-RX-API-DMAC10.html)
UA (1) UA125173C2 (cg-RX-API-DMAC10.html)
WO (1) WO2017085007A1 (cg-RX-API-DMAC10.html)
ZA (1) ZA201803167B (cg-RX-API-DMAC10.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018206619A1 (en) * 2017-05-11 2018-11-15 Chiesi Farmaceutici S.P.A. A process for preparing a dry powder formulation comprising an anticholinergic, a corticosteroid and a beta-adrenergic
WO2018206618A1 (en) * 2017-05-11 2018-11-15 Chiesi Farmaceutici S.P.A. A process for preparing a dry powder formulation comprising an anticholinergic, a corticosteroid and a beta-adrenergic
WO2019060595A1 (en) * 2017-09-20 2019-03-28 Teva Branded Pharmaceutical Products R&D, Inc. INHALABLE DRY POWDER MEDICINAL PRODUCT COMPRISING GLYCOPYRRONIUM
US11304901B2 (en) * 2019-08-28 2022-04-19 Anovent Pharmaceutical (U.S.), Llc Liposome formulation of fluticasone furoate and method of preparation
WO2021143785A1 (zh) * 2020-01-15 2021-07-22 四川海思科制药有限公司 一种含茚达特罗的吸入气雾剂药物组合物及其制备方法
CN111467498A (zh) * 2020-05-14 2020-07-31 王兆霖 药物组合物制剂
CN117064869B (zh) * 2023-09-27 2026-05-12 山东京卫制药有限公司 一种胶囊型吸入粉雾剂及其制备方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20011227A1 (es) * 2000-04-17 2002-01-07 Chiesi Farma Spa Formulaciones farmaceuticas para inhaladores de polvo seco en la forma de aglomerados duros
GB0015043D0 (en) 2000-06-21 2000-08-09 Glaxo Group Ltd Medicament dispenser
PT1386630E (pt) 2002-07-31 2006-09-29 Chiesi Farma Spa Inalador em po
EP1646370A1 (en) * 2003-07-11 2006-04-19 Glaxo Group Limited Pharmaceutical formulations
GB0410399D0 (en) * 2004-05-10 2004-06-16 Arakis Ltd The treatment of respiratory disease
RU2580312C2 (ru) 2010-04-21 2016-04-10 КЬЕЗИ ФАРМАЧЕУТИЧИ С.п.А. Способ получения частиц с пониженным электростатическим зарядом
US9393202B2 (en) 2013-04-26 2016-07-19 Chiesi Farmaceutici S.P.A Particle size reduction of an antimuscarinic compound
LT3019153T (lt) * 2013-07-11 2018-11-26 Chiesi Farmaceutici S.P.A. Sausų miltelių kompozicija, apimanti anticholinerginį agentą, kortikosteroidą ir beta-adrenerginį agentą, skirta įvedimui inhaliacijos pagalba

Also Published As

Publication number Publication date
ES2789365T3 (es) 2020-10-26
GEAP201614782A (cg-RX-API-DMAC10.html) 2020-04-27
TW201722403A (zh) 2017-07-01
CA3005291A1 (en) 2017-05-26
UA125173C2 (uk) 2022-01-26
SI3377109T1 (sl) 2020-07-31
WO2017085007A1 (en) 2017-05-26
AU2016357988B2 (en) 2021-12-16
BR112018009811A8 (pt) 2019-02-26
US10959944B2 (en) 2021-03-30
MX2018005979A (es) 2018-08-29
SI3689379T1 (sl) 2021-11-30
TWI729025B (zh) 2021-06-01
PH12018501023B1 (en) 2018-12-17
EP3377109A1 (en) 2018-09-26
JP6942126B2 (ja) 2021-09-29
HUE056402T2 (hu) 2022-02-28
CA3005291C (en) 2024-01-16
PT3689379T (pt) 2021-09-24
DK3689379T3 (da) 2021-09-06
KR20180082442A (ko) 2018-07-18
MA52437A (fr) 2021-05-05
CN108348614A (zh) 2018-07-31
PL3377109T3 (pl) 2020-09-21
GEP20207178B (en) 2020-11-10
US10786451B2 (en) 2020-09-29
PT3377109T (pt) 2020-05-13
AR106687A1 (es) 2018-02-07
AU2016357988A1 (en) 2018-05-31
ES2890409T3 (es) 2022-01-19
HUE050343T2 (hu) 2020-11-30
US10086003B2 (en) 2018-10-02
IL259327B (en) 2020-11-30
HRP20211599T1 (hr) 2022-01-07
PH12018501023A1 (en) 2018-12-17
EP3689379A1 (en) 2020-08-05
HK1256859A1 (zh) 2019-10-04
EP3377109B1 (en) 2020-03-04
EA037346B1 (ru) 2021-03-16
JP2018537453A (ja) 2018-12-20
EA201890967A1 (ru) 2018-12-28
MX377113B (es) 2025-03-07
SA518391574B1 (ar) 2021-06-13
HRP20200571T1 (hr) 2020-07-10
US20200360278A1 (en) 2020-11-19
BR112018009811A2 (pt) 2018-11-13
EP3689379B1 (en) 2021-08-11
PE20181377A1 (es) 2018-09-05
CL2018001297A1 (es) 2018-08-10
NZ742473A (en) 2024-11-29
PL3689379T3 (pl) 2021-12-13
IL259327A (en) 2018-07-31
US20190021994A1 (en) 2019-01-24
CN108348614B (zh) 2021-09-21
MY198321A (en) 2023-08-24
GEAP202014782A (en) 2020-04-27
DK3377109T3 (da) 2020-04-20
SG10201912090UA (en) 2020-02-27
US20170136034A1 (en) 2017-05-18
ZA201803167B (en) 2019-07-31
SG11201804048WA (en) 2018-06-28

Similar Documents

Publication Publication Date Title
CO2018005141A2 (es) Proceso para preparar una formulación en polvo seco que comprende un anticolinérgico, un corticosteroide y un beta-adrenérgico
MX2018005979A (es) Proceso para preparar una formulacion en polvo seco que comprende un anticolinergico, un corticosteroide y un beta-adrenergico.
MX2016000290A (es) Formulacion en polvo seco que comprende un anticolinergico, un corticosteroide y un beta-adrenergico para administrar por inhalacion.
CL2017002017A1 (es) Compuestos con actividad antagonista de los receptoresmuscarínicos y actividad agonista del receptor beta2 adrenérgico
CL2018003045A1 (es) Semaglutida en afecciones cardiovasculares.
TH1601000099A (th) สูตรผสมผงแห้งที่ประกอบรวมด้วยแอนติโคลิเนอร์จิก, คอร์ติโคสเตียรอยด์ และเบตา-แอดรีเนอร์จิกสำหรับการให้โดยการสูด